A goodness of fit test for multilevel survival data

No satisfactory goodness of fit test is available for multilevel survival data which occur when survival data are clustered or hierarchical in nature. Hence the aim of this research is to develop a new goodness of fit test for multilevel survival data and to examine the properties of the newly developed test. Simulation studies were carried out to evaluate the type ? error and the power. The results showed that the type I error holds for every combination tested and that the test is powerful against the alternative hypothesis of nonproportional hazards for all combinations tested.     

A general approximation to quantiles

For many continuous distributions, a closed-form expression for their quantiles does not exist. Numerical approximations for their quantiles are developed on a distribution-by-distribution basis. This work develops a general approximation for quantiles using the Taylor expansion. Our method only requires that the distribution has a continuous probability density function and its derivatives can be derived to a certain order (usually 3 or 4). We demonstrate our unified approach by approximating the quantiles of the normal, exponential, and chi-square distributions. The approximation works well for these distributions.     

Pitman closeness,monotonicity and consistency of best linear unbiased and invariant estimators for exponential distribution under Type II censoring

Comparisons of best linear unbiased estimators with some other prominent estimators have been carried out over the last 50 years since the ground breaking work of Lloyd [E.H. Lloyd, Least squares estimation of location and scale parameters using order statistics, Biometrika 39 (1952), pp. 88–95]. These comparisons have been made under many different criteria across different parametric families of distributions. A noteworthy one is by Nagaraja [H.N. Nagaraja, Comparison of estimators and predictors from two-parameter exponential distribution, Sankhyā Ser. B 48 (1986), pp. 10–18], who made a comparison of best linear unbiased (BLUE) and best linear invariant (BLIE) estimators in the case of exponential distribution. In this paper, continuing along the same lines by assuming a Type II right censored sample from a scaled-exponential distribution, we first compare BLUE and BLIE of the exponential mean parameter in terms of Pitman closeness (nearness) criterion. We show that the BLUE is always Pitman closer than the BLIE. Next, we introduce the notions of Pitman monotonicity and Pitman consistency, and then establish that both BLUE and BLIE possess these two properties.     

Bayesian adaptive dose‐escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy

The main purpose of dose‐escalation trials is to identify the dose(s) that is/are safe and efficacious for further investigations in later studies. In this paper, we introduce dose‐escalation designs that incorporate both the dose‐limiting events and dose‐limiting toxicities (DLTs) and indicative responses of efficacy into the procedure. A flexible nonparametric model is used for modelling the continuous efficacy responses while a logistic model is used for the binary DLTs. Escalation decisions are based on the combination of the probabilities of DLTs and expected efficacy through a gain function. On the basis of this setup, we then introduce 2 types of Bayesian adaptive dose‐escalation strategies. The first type of procedures, called “single objective,” aims to identify and recommend a single dose, either the maximum tolerated dose, the highest dose that is considered as safe, or the optimal dose, a safe dose that gives optimum benefit risk. The second type, called “dual objective,” aims to jointly estimate both the maximum tolerated dose and the optimal dose accurately. The recommended doses obtained under these dose‐escalation procedures provide information about the safety and efficacy profile of the novel drug to facilitate later studies. We evaluate different strategies via simulations based on an example constructed from a real trial on patients with type 2 diabetes, and the use of stopping rules is assessed. We find that the nonparametric model estimates the efficacy responses well for different underlying true shapes. The dual‐objective designs give better results in terms of identifying the 2 real target doses compared to the single‐objective designs.     

Estimation of the parameter of a dynamically selected population for two subclasses of the exponential family

We introduce the problem of estimation of the parameters of a dynamically selected population in an infinite sequence of random variables and provide its application in the statistical inference based on record values from a non stationary scheme. We develop unbiased estimation of the parameters of the dynamically selected population and evaluate the risk of the estimators. We provide comparisons with natural estimators and obtain asymptotic results. Finally, we illustrate the applicability of the results using real data.     

Cramér Asymptotic Efficiency in a Semiparametric Model

This article is concerned with efficient estimation in a semiparametric model. We consider pseudo maximum likelihood estimation and prove that the proposed estimator is asymptotically efficient in the sense of Cramér; that is, the estimator has the smallest mean squared error.     

Nonparametric Shrinkage Estimation for Aalen's Additive Hazards Model

Aalen's nonparametric additive model in which the regression coefficients are assumed to be unspecified functions of time is a flexible alternative to Cox's proportional hazards model when the proportionality assumption is in doubt. In this paper, we incorporate a general linear hypothesis into the estimation of the time‐varying regression coefficients. We combine unrestricted least squares estimators and estimators that are restricted by the linear hypothesis and produce James‐Stein‐type shrinkage estimators of the regression coefficients. We develop the asymptotic joint distribution of such restricted and unrestricted estimators and use this to study the relative performance of the proposed estimators via their integrated asymptotic distributional risks. We conduct Monte Carlo simulations to examine the relative performance of the estimators in terms of their integrated mean square errors. We also compare the performance of the proposed estimators with a recently devised LASSO estimator as well as with ridge‐type estimators both via simulations and data on the survival of primary billiary cirhosis patients.     

侵权人不明的高楼落物侵权的法律规制

《侵权责任法》第87条对侵权人不明的高楼落物侵权责任的承担进行了规定,具有保障受害人得到补偿、统一司法实践、降低致害概率的积极意义。但是,该规定也存在许多不足之处,主要表现为不利于社会和谐、容易引发道德风险、预防功能不充分、适用前提不明确等,没有很好地解决高楼落物侵权所面临的困境。采取社会救济、高楼落物赔偿基金、保险赔偿等多种途径相结合的救济方式,行政法、刑法与《侵权责任法》相配合的惩罚制度,不仅可以使受害人得到及时的、充分的补偿,而且可以有效预防此类侵权损害的发生。     

Classical estimation of hazard rate and mean residual life functions of Pareto distribution

Abstract

In this paper we find the maximum likelihood estimates (MLEs) of hazard rate and mean residual life functions (MRLF) of Pareto distribution, their asymptotic non degenerate distribution, exact distribution and moments. We also discuss the uniformly minimum variance unbiased estimate (UMVUE) of hazard rate function and MRLF. Finally, two numerical examples with simulated data and real data set, are presented to illustrate the proposed estimates.